Business
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that it intends to offer $140.0 million aggregate principal amount of convertible senior notes due 2031, subject to market and other conditions. Evolent also expects to grant the initial purchasers in the proposed offering an option to purchase up to an additional $20.0 million aggregate principal amount of notes. The notes are being offered only
About this update from Evolent Health, Inc
[{"type":"text","content":"WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that it intends to offer $140.0 million aggregate principal amount of convertible senior notes due 2031, subject to market and other conditions. Evolent also expects to grant the initial purchasers in the proposed offering an option to purchase up to an additional $20.0 million aggregate principal amount of notes. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").","length":721,"tagName":"p"},{"type":"text","content":"Evolent intends to use up to $100.0 million of the net proceeds from the offering to repurchase a portion of Evolent's 1.50% convertible senior notes due 2025 (the "2025 Notes") and approximately $40.0 million of the net proceeds of the offering to repurchase shares of its Class A common stock concurrently with the pricing of the offering in privately negotiated transactions. Evolent expects to use the remainder of the net proceeds from the offering, if any, for the repurchase or repayment at maturity of additional 2025 Notes. If the initial purchaser exercises its option to purchase additional notes, Evolent expects to use the net proceeds from the sale of the additional notes to repurchase or repay at maturity additional 2025 Notes.","length":768,"tagName":"p"},{"type":"text","content":"In connection with the concurrent share repurchase described above, Evolent expects to repurchase shares of its Class A common stock sold short by initial investors in the offering in privately negotiated transactions effected with or through the initial purchaser or its affiliate at a purchase price per share equal to the last reported sale price per share of Evolent's Class A common stock on the pricing date of the offering. These repurchases could increase (or reduce the size of any decrease in) the market price of Evolent's Class A common stock or the notes. In the case of repurchases effected concurrently with the offering, this activity could affect the market price of Evolent's Class A common stock prior to, concurrently with...